Dewpoint Therapeutics and ConcertAI Announce the First Phase of their Translational Oncology Partnership
12 déc. 2024 07h00 HE
|
Dewpoint Therapeutics
BOSTON and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s...
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
04 déc. 2024 08h00 HE
|
Dewpoint Therapeutics
- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients - Mitsubishi...
Dewpoint Therapeutics Announces Nomination of First C-Mod Development Candidate DPTX3186 for Treatment of Wnt-Driven Cancers
28 oct. 2024 08h00 HE
|
Dewpoint Therapeutics
Orally administered small molecule condensate modulators (c-mods) are a novel class of therapeutic agents designed to target condensates to modify diseaseDPTX3186 is Dewpoint’s first development...
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
24 oct. 2024 08h00 HE
|
Dewpoint Therapeutics
Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutationsPost-licensing,...
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amyotrophic Lateral Sclerosis (ALS)
26 août 2024 09h00 HE
|
Dewpoint Therapeutics
Grant to support the in vivo development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Dewpoint...
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS
16 janv. 2024 09h00 HE
|
Dewpoint Therapeutics
The in-kind Target ALS Foundational grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS animal model BOSTON, Jan. ...
Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS
07 janv. 2024 15h00 HE
|
Dewpoint Therapeutics
Patent applications reinforce Dewpoint’s leadership in the discovery of condensate-modifying drugs (c-mods) to treat diseases of high unmet needNew first-in-class composition of matter targeting...
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
07 nov. 2023 01h30 HE
|
Dewpoint Therapeutics
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY...